In addition to B cell depletion therapy, attempts to reduce B cell survival and modulate B cell function have been trialed in MS by inhibiting the activity of BAFF/APRIL using Atacicept, a soluble TACI receptor that binds both BAFF and APRIL and appears effective in reducing pathology in other autoimmune diseases such as systemic lupus erythematosus (22). The gene discussed is TNFSF13; the disease is myeloid sarcoma.